In addition to 4PBA, a variety of Hsc70 inhibitors are being examined as potential correctors of ΔF508-CFTR trafficking and may also represent therapeutic targets for treatment of CF (see Figure 3). This evidence concerns the gene CFTR and cystic fibrosis.